Pernix治疗控股 PTXTQ 深 沪
已收盘 03-05 16:00:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 --
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
Houston-based Plus Therapeutics subsidiary CNSide Diagnostics will launch its CSF assay platform for detecting cancer metastases in the central nervous system in Texas in August 2025. The initial commercial focus will be on NCI-Designated Cancer Centers and large healthcare systems. The CNSide assay offers high sensitivity (92%) and specificity (95%), surpassing traditional CSF cytology methods. It has been used in over 11,000 tests since 2020 an...
07-31 11:30
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Phathom Pharmaceuticals将举行电话会议，于2025年8月7日上午8点EDT，讨论2025年第二季度财务结果及业务更新。会议直播及更多信息可访问公司官网https://investors.phathompharma.com/news-events/events-and-presentations。录音将保存90天。公司专注于胃肠道疾病治疗产品的研发与商业化，其核心产品为vonoprazan。
07-28 12:00
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
Plus Therapeutics has received a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a $17.6 million grant to support its targeted radiotherapeutic development program for leptomeningeal cancer. The funding will accelerate the ReSPECT-LM clinical trial and further develop the CNSide LM diagnostic test. CPRIT, the second-largest public cancer research funder globally, joins the NIH and DoD in ...
07-23 11:30
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Houston-based Plus Therapeutics has initiated the ReSPECT-LM dose optimization trial for REYOBIQ, targeting leptomeningeal metastases (LM). Building on Phase 1 results, the trial aims to determine optimal dosing regimens for maximum safety and efficacy, supported by a $17.6M CPRIT grant. Previously, the single-dose trial demonstrated a 76% clinical benefit rate and no dose-limiting toxicities in early cohorts. The ReSPECT-LM trial will enroll up ...
06-30 11:30
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treating serious, rare genetic skin diseases without FDA-approved therapies, has been added to the Russell 3000® and Russell 2000® indexes effective June 30, 2025. Membership in these indexes reflects the company's market capitalization and is part of the annual reconstitution process. Palvella is developing a pipeline of product candidates, including its lead QTOR...
06-30 11:30
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Phathom Pharmaceuticals has granted inducement awards to Anne Marie Cook upon her appointment as Chief Legal Officer and Corporate Secretary. The awards include non-qualified stock options for 210,000 shares, vesting over four years, and performance-based stock units tied to financial goals over three years, under the 2025 Inducement Plan. Phathom specializes in novel treatments for gastrointestinal diseases and markets vonoprazan-based products,...
06-23 20:15
